SCHEMBL3105290

SCHEMBL3105290

CC1CCN(c2cc(C(=O)O)nc(N3CCOCC3)n2)CC1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 2/20 0.51
KMO O15229 1/20 0.51
ALDH1A1 P00352 3/20 0.49
KDM4E B2RXH2 2/20 0.49
MEN1 O00255 1/20 0.49
GAA P10253 1/20 0.49
THRB P10828 1/20 0.49
SMN1; SMN2 Q16637 1/20 0.49
NAPEPLD Q6IQ20 6/20 0.48
NPSR1 Q6W5P4 2/20 0.46
HRH4 Q9H3N8 1/20 0.46
MAPK1 P28482 2/20 0.45
MAPT P10636 2/20 0.45
HSD17B10 Q99714 2/20 0.44
GBA1 P04062 2/20 0.44
HPGD P15428 1/20 0.44
PIK3CA P42336 2/20 0.44
LMNA P02545 1/20 0.44
POLB P06746 1/20 0.44
HTT P42858 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1271891 0.89 KMO (0.61) KMT2AKMOALDH1A1KDM4EMEN1
SCHEMBL3118342 0.89 KMO (0.52) KMT2AKMOALDH1A1KDM4EMEN1
SCHEMBL3114736 0.85 KMO (0.49) KMT2AKMOALDH1A1KDM4EMEN1
SCHEMBL3114998 0.84 KMO (0.56) KMT2AKMOALDH1A1KDM4EMEN1
SCHEMBL3116377 0.84 PIK3CA (0.50) KMT2AKMOALDH1A1KDM4EMEN1
SCHEMBL3113412 0.79 KMO (0.50) KMT2AKMOALDH1A1KDM4EMEN1
SCHEMBL3100732 0.78 KMO (0.49) KMT2AKMOALDH1A1KDM4EMEN1
SCHEMBL3107368 0.77 HSD17B10 (0.57) KMOALDH1A1KDM4ESMN1; SMN2NAPEPLD
SCHEMBL6651425 0.77 POLB (0.64) KMT2AKMOALDH1A1KDM4EMEN1
SCHEMBL3113600 0.77 KMT2A (0.60) KMT2AALDH1A1KDM4ESMN1; SMN2NPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100256132-A1 IL-12 MODULATORY COMPOUNDS SYNTA PHARMACEUTICALS CORPORATION (US) 2010-10-07 US claimed
EP-1819341-A2 IL-12 MODULATORY COMPOUNDS Synta Pharmaceuticals Corporation (US) 2007-08-22 EP claimed
US-20060223996-A1 IL-12 modulatory compounds SYNTA PHARMACEUTICALS CORP. (US) 2006-10-05 US claimed
WO-2006053227-A2 IL-12 MODULATORY COMPOUNDS SYNTA PHARMACEUTICALS CORP. (US) 2006-05-18 WO claimed
US-8236795-B2 IL-12 modulatory compounds SYNTA PHARMACEUTICALS CORP. (US) 2012-08-07 US disclosed
US-20100256132-A1 IL-12 MODULATORY COMPOUNDS SYNTA PHARMACEUTICALS CORPORATION (US) 2010-10-07 US disclosed
US-7696202-B2 IL-12 modulatory compounds SYNTA PHARMACEUTICALS CORP. (US) 2010-04-13 US disclosed
EP-1819341-A2 IL-12 MODULATORY COMPOUNDS Synta Pharmaceuticals Corporation (US) 2007-08-22 EP disclosed
US-20060223996-A1 IL-12 modulatory compounds SYNTA PHARMACEUTICALS CORP. (US) 2006-10-05 US disclosed
WO-2006053227-A2 IL-12 MODULATORY COMPOUNDS SYNTA PHARMACEUTICALS CORP. (US) 2006-05-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060223996-A1 IL-12 modulatory compounds IL2, IL4, IFNG KMT2A 3672/4885KMO 1707/4885ALDH1A1 1381/4885
US-20100256132-A1 IL-12 MODULATORY COMPOUNDS IL2, IL4, IFNG KMT2A 3672/4885KMO 1707/4885ALDH1A1 1381/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.